Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease
Pasquale Mone, Germano Guerra, Angela Lombardi, Maddalena Illario, Antonella Pansini, Anna Marro, Salvatore Frullone, Alessandro Taurino, Daniela Sorriento, Veronica Verri, Guido Iaccarino, Gaetano Santulli
Abstract
Chronic kidney disease (CKD) is a relatively common condition in patients with type
Topics & Concepts
EmpagliflozinMedicineKidney diseaseDiabetes mellitusCognitive impairmentDiseaseType 2 diabetesPharmacologyInternal medicineEndocrinologyDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesNutrition and Health in Aging